

Vimta Labs Limited

Registered Office
142, IDA Phase II, Cherlapally
Hyderabad-500 051, Telangana, India
T : +91 40 2726 4141
F : +91 40 2726 3657



VLL\SE\011\2024-25
Date: 18.05.2024

Listing Centre
B S E Limited
P J Towers, Dalal Street
Mumbai: 400001
Scrip Code No.524394

Asst Vice President
National Stock Exchange of India Limited
"Exchange Plaza", Bandra
Kurla Complex, Bandra (E)
Mumbai – 400051
Trading Symbol: VIMTALABS

Dear Sir/Madam,

Sub – Press Release – Audited Financial Results – 31st March 2024.

Pursuant to Regulation 30 of SEBI (Listing obligations and disclosure requirements) 2015, please find enclosed the press release in connection with announcement of Audited Standalone and Consolidated Financial Results for the 4th Quarter and financial year ended 31st March 2024.

This is for your information and records.

Thanking you,

Yours faithfully,
for VIMTA LABS LIMITED

Sujani Vasireddi
Company Secretary

Encl: as above.



Vimta Labs Limited Reports Q4 & FY24 Results

**Q4 FY24 Total Income at Rs. 802 Mn,
EBITDA margins at 31.1%; PAT margin at 15.4%**

Hyderabad, May 18, 2024: Vimta Labs Limited (VIMTA) (BSE: 524394, NSE: VIMTALABS), India's leading Contract Research and Testing Organisation, has announced its financial results for the quarter and year ended March 31, 2024.

Consolidated Financial Results – Q4 & FY24:

Particulars (Rs. Mn)	Q4FY24	Q4FY23	YoY	FY24	FY23	YoY
Total Income	802	825	-2.8%	3,223	3,216	0.2%
EBITDA (including other income)	249	248	0.3%	908	984	-7.7%
EBITDA Margin	31.1%	30.1%		28.2%	30.6%	
PAT	124	127	-2.6%	410	482	-14.9%
PAT Margin	15.4%	15.4%		12.7%	15.0%	
Basic EPS	5.6	5.7	-2.5%	18.5	21.8	-14.9%

Commenting on results, Ms. Harita Vasireddi, Managing Director, Vimta Labs Limited, said: *“Q4 maintained good recovery after H1 being harsh on us. Having a strong and resilient business model has helped us strive through some headwinds and get back to the historical figures.*

Our services to the Pharmaceutical industry have seen a promising uptick, demonstrating growth in both pre-clinical and analytical services. We have recently expanded our offerings to include clinical trials, which we anticipate will be a major driver of future growth.

The Food segment experienced initial setbacks due to supply chain disruptions caused by various external factors. However, this segment has begun to recover and shows promise for continued improvement. Our new Electronics and Electrical testing division delivered strong results, while our other segments have gone through some corrections in services and their scale.

Looking forward, we are confident in our ability to achieve significant growth. While FY24 presented unforeseen challenges, we are optimistic that FY25 will be a year of robust expansion for the company.”

Key Result Highlights for the Q4 & FY24 (Consolidated):

Q4 FY24

- ✓ Total Income for Q4FY24 was at Rs. 802 Mn
- ✓ EBITDA for Q4FY24 was Rs. 249 Mn; EBITDA margin was at 31.1%

PRESS RELEASE

For Immediate dissemination



- ✓ Q4FY24 PAT was at Rs. 124 Mn
- ✓ Basic EPS in Q4FY24 was Rs. 5.6

FY24

- ✓ Total Income for FY24 was at Rs. 3,223 Mn
- ✓ EBITDA for FY24 was Rs. 908 Mn; EBITDA margins at 28.2%
- ✓ FY24 PAT was at Rs. 410 Mn
- ✓ Basic EPS was Rs. 18.5 in FY24
- ✓ Cash flow From Operations at Rs. 609 Mn for FY24; FY24 Capex at Rs. 763 Mn
- ✓ Cash and Cash equivalents at Rs. 258 Mn as of 31st March 2024
- ✓ Debt to Equity ratio 0.06x

Operational Highlights

- ✓ During the year, the company re-strategized its services portfolio providing greater impetus for driving growth in food, pharma, and electronics testing while other industry services were optimized based on their returns.
- ✓ Initiated long term partnerships with globally leading pharmaceutical and animal health companies.
- ✓ Pharmaceuticals saw a good uptick in the Clinical, Pre-Clinical and Analytical Services.
- ✓ Satisfactory performance in several regulatory audits/reviews during the year from various agencies such as USFDA, EMA, WHO, NGCMA, FSSAI, and DCA.
- ✓ Embarked on doubling capacities in the Genome Valley, Hyderabad campus to gear up for our growth for next 5 years. The expansion project which will add ~200,000 sf. ft. of additional space for labs and support functions.
- ✓ Successfully completed 2 years of operation of the National Food Lab, at Navi Mumbai; in PPP mode with FSSAI.

ABOUT VIMTA LABS LIMITED:

Founded in 1984 with headquarters in Hyderabad, India, VIMTA LABS LTD., is a leading contract research and testing organization, providing food, agri, bio/pharmaceutical, medical device, speciality chemical, and electronics companies an integrated scientific, technical, and regulatory expertise to support all stages of product development and manufacturing process. Vimta also provides clinical diagnostic services and environmental assessments and testing services.

CAUTIONARY STATEMENT:

This press release may contain certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may

PRESS RELEASE

For Immediate dissemination



differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and Vimta Labs Limited has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

For details, please contact:

<p>Investor Relations at Vimta Labs Narahai Naidu Dodda, CFO Narahai.Dodda@vimta.com</p> <p>Ernst & Young Mr. Siddesh Chawan Siddesh.Chawan@in.ey.com</p> <p>Mr. Advait Bhadekar Advait.bhadekar@in.ey.com</p>	<p>Registered Office Plot Number 142, IDA Phase 2 Cherlapally, Hyderabad Telangana, India. 500051 CIN: L24110TG1990PLC011977 ISIN: INE579C01029 NSE Code: VIMTALABS BSE CODE: 524394 Website: www.vimta.com</p>
--	---